British BioTech company innovating 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases
Enhanced Genomics has raised €16M across 1 funding round from 3 investors, most recently a Series A round in Sep 2025. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-17 | Series A | €16M |
| BGF,Meltwind,Parkwalk |
| View deal → |
